Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profiling of all KMT2B-WT, HT, and Int HPCs. KMT2B-HT and Int iPSCs

ABSTRACT: Transcriptional profiling of all KMT2B-WT, HT, and Int HPCs. KMT2B-HT and Int iPSCs

PROVIDER: PRJNA901871 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptional profiling of all KMT2B-WT, HT, and Int HPCs. KMT2B-HT and Int iPSCs

Project description:HBV-KMT2B integrated human induced pluripotent stem cell-derived hepatic progenitor cells (KMT2B-Int HPCs) vs heterozygous mutated KMT2B human induced pluripotent stem cell-derived hepatic progenitor cells (KMT2B-HT HPCs) vs original human induced pluripotent stem cell-derived hepatic progenitor cells (KMT2B-WT HPCs) Transcriptional profiling of all KMT2B-WT, HT, and Int HPCs. KMT2B-HT and Int iPSCs were generated by gene editing using CRISPR/Cas9 and Cre recombinase technologies. iPSCs were differentiated into a hepatic lineage. On Day14 of hepatic differentiation, CD13 high and C133 high hepatic cells were sorted by fluorescence-activated cell sorter (FACS) on feeder mouse embryonic fibroblasts (MEFs). HPCs forms colony on MEFs and were stably cultured with maintaining their hepatic phenotype.

2025-01-01 | GSE217993 | GEO

HBV-KMT2B integrated human induced pluripotent stem cells (KMT2B-Int iPSCs) vs heterozygous mutated KMT2B iPSCs (KMT2B-HT iPSCs) vs homozygous mutated KMT2B iPSCs (KMT2B-KO iPSCs) vs their original iPSCs (KMT2B-WT iPSCs)

Project description:Transcriptional profiling of all KMT2B-WT, HT, KO, Int iPSCs. KMT2B-HT, KO, and Int iPSCs were generated by gene editing using CRISPR/Cas9 and Cre recombinase technologies.

2023-11-15 | GSE217994 | GEO

Project description:HBV-KMT2B integrated human induced pluripotent stem cells (KMT2B-Int iPSCs) vs heterozygous mutated KMT2B iPSCs (KMT2B-HT iPSCs) vs homozygous mutated KMT2B iPSCs (KMT2B-KO iPSCs) vs their original iPSCs (KMT2B-WT iPSCs)

| PRJNA901875 | ENA

CUT＆Tag analysis of HBV-KMT2B integrated HPCs and KMT2B heterozygous knockout HPCs

Project description:To investigate the global analysis of H3K4me3 of HBV-KMT2B integrated HPCs, CUT＆Tag analysis of HBV-KMT2B integrated HPCs and KMT2B heterozygous knockout HPCs was performed.

2025-01-01 | GSE244039 | GEO

CUT＆Tag analysis of HBV-KMT2B integrated HPCs and KMT2B heterozygous knockout HPCs

Project description:CUT＆Tag analysis of HBV-KMT2B integrated HPCs and KMT2B heterozygous knockout HPCs

| PRJNA1021151 | ENA

Long-read RNA-seq(Iso-seq) analysis of HBV-KMT2B integrated HPCs in which HBV genome is integrated into KMT2B region.

Project description:We identified full-length complementary DNA by long-read RNA-seq (Iso-seq) in HBV-KMT2B integrated HCC sample. To compare the data of HCC sapmle with HBV-KMT2B integrated HPCs, which reproduces the sequence of the HCC sample, we performed long-read RNA-seq in HBV-KMT2B integrated HPCs, as well.

2025-01-01 | GSE244522 | GEO

Long-read RNA-seq(Iso-seq) analysis of HBV-KMT2B integrated HPCs in which HBV genome is integrated into KMT2B region.

Project description:Long-read RNA-seq(Iso-seq) analysis of HBV-KMT2B integrated HPCs in which HBV genome is integrated into KMT2B region.

| PRJNA1023476 | ENA

Gene expression profiling of pre-HPCs derived from CML-iPSCs

Project description:Properties of cancer stem cells (CSC) involved in drug-resistance and relapse have significant effect on clinical outcome. Although tyrosine kinase inhibitors (TKIs) have dramatically improved survival of patients with chronic myelogenous leukemia (CML), TKIs have not fully cure CML due to TKI-resistant CML stem cells. Moreover, the relapse after discontinuation of TKIs has not been predicted in CML patients with best TKI-response. In our study, pre-hematoopoietic progenitor cells (pre-HPCs), a model of CML stem cells derived from CML-iPSCs identified a novel antigen of TKI-resistant CML cells. Even in the fraction reported as TKI-sensitive, the antigen+ cells showed TKI-resistance in CML patients. In addition, residual CML cells in patients with optimal TKI-response were concentrated in the antigen+ population.

2016-12-21 | GSE92624 | GEO

Effects of KRAS (G13C) expression on transcriptome profiles assessed in HPCs differentiated from patient-derived iPS cells

Project description:How a single oncogenic RAS impacts non-transformed hematopoietic progenitor cells (HPCs) remains largely unknown. We therefore investigated how a monoallelic KRAS mutation (G13C) affected HPCs utilizing induced pluripotent stem cells (iPSCs) derived from two unrelated patients with RAS-associated autoimmune lymphoproliferative syndrome-like disease (RALD).

2024-04-01 | GSE200600 | GEO

RNA-seq analysis of HeLa cells overexpressing histone methyltransferase KMT2B

Project description:KMT2B，a major H3K4 tri-methyltransferase, contributes to the development of various cancers. However, its role in cervical cancer is unclear. We found that KMT2B is upregulated in cervical cancer tissues, which is significantly associated with poor prognosis.To investigate the underlying mechanism of KMT2B in the progression of cervical cancer, we established stable KMT2B-overexpression HeLa cells.Then we compared the whole genome mRNA expression profile of KMT2B overexpression and control HeLa cells using RNA-seq.

2022-08-03 | GSE209928 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data